Express News | Shandong Xinhua Pharmaceutical - Pentazocine Injection Obtained Drug Registration Certificate From Npa China

Reuters04:36 ET

National People's Congress representative, Zhao Jing of Shandong Buchang Pharmaceuticals: "The 'AI+' is reaching a critical point of explosion. It is recommended to utilize AI to empower the inheritance and innovation of Traditional Chinese Medicine | Two

① Zhao Jing, a representative of the National People's Congress and Vice Director of Shandong Buchang Pharmaceuticals, brought the proposal "Utilizing AI to Empower the Inheritance and Innovation of Traditional Chinese Medicine and Build a New Pattern of Development for Traditional Chinese Medicine with 'Asia Vets + Technology'" to this year's Two Sessions, aiming to promote the intelligent upgrade of the Traditional Chinese Medicine industry through AI technology. ② Zhao Jing stated that the development of large models like DeepSeek has indeed pushed the integration of Traditional Chinese Medicine and AI to a critical point of explosion.

cls.cnMar 6 20:48 ET

The investment secrets in the government work report: Analyzing the collaborative logic of the Global Strategy and policies of Guoshengtang (2273.HK).

The report clearly states to strengthen basic Medical and health services.

Gelonghui FinanceMar 5 20:15 ET

The bull market for Hong Kong stocks has begun; how to identify the certainty of value growth?

At present, the technical bull market in the Hong Kong stock market is becoming the focus of attention for global investors.

Gelonghui FinanceMar 3 19:44 ET

Shandong Xinhua Pharmaceutical (000756.SZ): The supplementary application for the transfer of the marketing authorization holder for Clopidogrel Bisulfate tablets has been approved.

On March 3rd, Gelonghui reported that Shandong Xinhua Pharmaceutical (000756.SZ) announced that recently, SHANDONG XINHUA received the approval notice for the supplementary application of the hydrogen chloride clopidogrel tablets (referred to as "this product") issued by the National Medical Products Administration, approving the transfer of this product's marketing authorization holder. The hydrogen chloride clopidogrel tablets are a medication for circulatory system diseases and are a prodrug, with one of its metabolites being a platelet aggregation inhibitor. Clopidogrel must be metabolized by the CYP450 enzyme to generate active metabolites that can inhibit platelet aggregation. The active metabolites of clopidogrel selectively inhibit.

Gelonghui FinanceMar 3 03:40 ET

SHANDONG XINHUA (00719.HK): received the approval notice for the supplementary application of the pharmaceutical.

Gelonghui March 3rd丨SHANDONG XINHUA (00719.HK) announced that recently, the company received the "Pharmaceutical Supplement Application Approval Notice" issued by the National Medical Products Administration, approving the transfer of the supplementary application for the listing license holder of the clopidogrel hydrogen sulfate tablets (hereinafter referred to as "this product").

Gelonghui FinanceMar 3 03:32 ET